Skip to main content
Erschienen in: Tumor Biology 12/2014

01.12.2014 | Research Article

Essential role of polymorphism of Gab1, EGFR, and EGF for the susceptibility of biliary tract cancer

verfasst von: Ling-qin Meng

Erschienen in: Tumor Biology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Cholangiocarcinoma is a malignant neoplasm arising from the epithelial cells lining the biliary ducts and its occurrence can be anatomically classified as within the liver (intrahepatic) or outside the liver (extrahepatic). Extrahepatic cholangiocarcinoma, which can be called as biliary tract cancer (BTC), is the most common form of this malignancy, and its etiology is still unclear. In this study, we tried to elucidate the complicated association between receptor tyrosine kinase (RTK) gene polymorphisms and susceptibility of BTC by analyzing frequency distribution of genotypes and alleles of GRB2-associated-binding protein 1 (Gab1), endothelial growth factor receptor (EGFR), and endothelial growth factor (EGF) and identified potential risk of BTC for people carrying specific genotype of Gab1 and EGFR. Two hundred twenty-five and 300 patients with BTC and cholelithiasis (gallstone (GS)), respectively, and 300 controls matched by age, sex, and ethnicity with patients were recruited from Shengjing Hospital of China Medical University from January 2008 to July 2011 with informed consents. Genomic DNA of BTC group was extracted and purified from formalin-fixed, paraffin-embedded tumor tissue sections using QiAamp DNA FFPE Tissue kit. For GS group and controls, DNA was extracted from peripheral blood leukocytes using genomic DNA extraction kit from Aid Lab. Target genes of RTK family were identified from National Center of Biotechnology Information (NCBI) SNP database and Japanese Single Nucleotide Polymorphisms (JSNP) database. Frequency distribution of genotypes and alleles was analyzed using HapMap Project database. All of the statistical analysis was conducted with SPSS 13.0 software. Eight loci were identified for Gab1 (4), EGFR (3), and EGF (1) as the target single-nucleotide polymorphisms (SNPs) for the association of gene polymorphisms and BTC. A/A genotype and A allele of rs3805246 in Gab1 and G/G genotype and G allele of rs2017000 in EGFR were significantly higher in BTC group than in GS group or controls. After controlling for BMI, age, gender, and smoking habit, patients with “A/A + G/A” had 2.154 times odds to have BTC; as for patients with “A/A” only, they still had 1.976 times odds to have BTC. In the rs2017000 of EGFR, patients with “G/G + G/A” had 1.772 times odds to have BTC, and patients with “G/G” only had 1.530 times odds to have BTC. Furthermore, patients with A/A in rs3805246 and G/G in rs2017000 simultaneously had 1.620 times chance to have BTC than people with other genotypes. This study explored the independent potential effect of EGFR signaling transduction pathway and its downstream element Gab1 and the gene-gene interaction on the disease mechanism of BTC in the perspective of genetics and molecular epidemiology.
Literatur
1.
Zurück zum Zitat Baghbanian M, Salmanroghani H, Baghbanian A. Cholangiocarcinoma or Caroli disease: a case presentation. Gastroenterol Hepatol Bed Bench. 2013;6:214–6.PubMedPubMedCentral Baghbanian M, Salmanroghani H, Baghbanian A. Cholangiocarcinoma or Caroli disease: a case presentation. Gastroenterol Hepatol Bed Bench. 2013;6:214–6.PubMedPubMedCentral
2.
Zurück zum Zitat Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. British Society of G: guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51 Suppl 6:VI1–9.PubMedPubMedCentral Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. British Society of G: guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51 Suppl 6:VI1–9.PubMedPubMedCentral
3.
Zurück zum Zitat Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6–29.CrossRef Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6–29.CrossRef
4.
Zurück zum Zitat Castro FA, Koshiol J, Hsing AW, Devesa SS. Biliary tract cancer incidence in the united states-demographic and temporal variations by anatomic site. Int J Cancer J Int Cancer. 2013;133:1664–71.CrossRef Castro FA, Koshiol J, Hsing AW, Devesa SS. Biliary tract cancer incidence in the united states-demographic and temporal variations by anatomic site. Int J Cancer J Int Cancer. 2013;133:1664–71.CrossRef
5.
Zurück zum Zitat Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349–64.CrossRef Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349–64.CrossRef
6.
Zurück zum Zitat McNamara MG, Walter T, Horgan AM, Amir E, Cleary S, McKeever EL, Min T, Wallace E, Hedley D, Krzyzanowska M, Moore M, Gallinger S, Greig P, Serra S, Dawson LA, Knox JJ. Outcome of adjuvant therapy in biliary tract cancers. Am J Clin Oncol. 2013 McNamara MG, Walter T, Horgan AM, Amir E, Cleary S, McKeever EL, Min T, Wallace E, Hedley D, Krzyzanowska M, Moore M, Gallinger S, Greig P, Serra S, Dawson LA, Knox JJ. Outcome of adjuvant therapy in biliary tract cancers. Am J Clin Oncol. 2013
7.
Zurück zum Zitat Eftekhar E, Rasti M, Nahgibalhossaini F, Sadeghi Y. The study of DNA methyltransferase-3b promoter variant genotype among Iranian sporadic breast cancer patients. Iran J Med Sci. 2014;39:268–74.PubMedPubMedCentral Eftekhar E, Rasti M, Nahgibalhossaini F, Sadeghi Y. The study of DNA methyltransferase-3b promoter variant genotype among Iranian sporadic breast cancer patients. Iran J Med Sci. 2014;39:268–74.PubMedPubMedCentral
8.
Zurück zum Zitat Bozdogan ST, Erol B, Dursun A, Bozdogan G, Donmez I, Mungan NA, Seydaoglu G: The il-1rn and il-4 gene polymorphisms are potential genetic markers of susceptibility to bladder cancer: a case-control study. World J Urol. 2014 Bozdogan ST, Erol B, Dursun A, Bozdogan G, Donmez I, Mungan NA, Seydaoglu G: The il-1rn and il-4 gene polymorphisms are potential genetic markers of susceptibility to bladder cancer: a case-control study. World J Urol. 2014
9.
Zurück zum Zitat Peng Y, Guo JJ, Liu YM, Wu XL. Microrna-34a inhibits the growth, invasion and metastasis of gastric cancer by targeting pdgfr and met expression. Biosci Rep. 2014 Peng Y, Guo JJ, Liu YM, Wu XL. Microrna-34a inhibits the growth, invasion and metastasis of gastric cancer by targeting pdgfr and met expression. Biosci Rep. 2014
10.
Zurück zum Zitat Rothlin CV, Leighton JA, Ghosh S. Tyro3, axl, and mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflamm Bowel Dis. 2014;20(8):1472–80.CrossRef Rothlin CV, Leighton JA, Ghosh S. Tyro3, axl, and mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflamm Bowel Dis. 2014;20(8):1472–80.CrossRef
11.
Zurück zum Zitat Im YK, La Selva R, Gandin V, Ha JR, Sabourin V, Sonenberg N, Pawson T, Topisirovic I, Ursini-Siegel J: The shca adaptor activates Akt signaling to potentiate breast tumor angiogenesis by stimulating vegf mRNA translation in a 4e-bp-dependent manner. Oncogene. 2014 Im YK, La Selva R, Gandin V, Ha JR, Sabourin V, Sonenberg N, Pawson T, Topisirovic I, Ursini-Siegel J: The shca adaptor activates Akt signaling to potentiate breast tumor angiogenesis by stimulating vegf mRNA translation in a 4e-bp-dependent manner. Oncogene. 2014
12.
Zurück zum Zitat Koh YW, Lee HJ, Ahn JH, Lee JW, Gong G. Met expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting. Pathol Res Pract. 2014;210(8):494–500.CrossRef Koh YW, Lee HJ, Ahn JH, Lee JW, Gong G. Met expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting. Pathol Res Pract. 2014;210(8):494–500.CrossRef
13.
Zurück zum Zitat Dokduang H, Juntana S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, et al. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:3519–28.CrossRef Dokduang H, Juntana S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, et al. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:3519–28.CrossRef
14.
Zurück zum Zitat Hoffmann AC, Goekkurt E, Danenberg PV, Lehmann S, Ehninger G, Aust DE, et al. Egfr, flt1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma. PLoS One. 2013;8:e64186.CrossRef Hoffmann AC, Goekkurt E, Danenberg PV, Lehmann S, Ehninger G, Aust DE, et al. Egfr, flt1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma. PLoS One. 2013;8:e64186.CrossRef
15.
Zurück zum Zitat Srivastava K, Srivastava A, Sharma KL, Mittal B. Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis. Mutat Res. 2011;728:67–79.CrossRef Srivastava K, Srivastava A, Sharma KL, Mittal B. Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis. Mutat Res. 2011;728:67–79.CrossRef
16.
Zurück zum Zitat La Vecchia C, Negri E. A review of epidemiological data on epilepsy, phenobarbital, and risk of liver cancer. Eur J Cancer Prev Off J Eur Cancer Prev Organ. 2014;23:1–7.CrossRef La Vecchia C, Negri E. A review of epidemiological data on epilepsy, phenobarbital, and risk of liver cancer. Eur J Cancer Prev Off J Eur Cancer Prev Organ. 2014;23:1–7.CrossRef
17.
Zurück zum Zitat Andreotti G, Chen J, Gao YT, Rashid A, Chen BE, Rosenberg P, et al. Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2008;17:525–34.CrossRef Andreotti G, Chen J, Gao YT, Rashid A, Chen BE, Rosenberg P, et al. Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2008;17:525–34.CrossRef
18.
Zurück zum Zitat Srivastava A, Sharma KL, Srivastava N, Misra S, Mittal B. Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy. PLoS One. 2012;7:e40162.CrossRef Srivastava A, Sharma KL, Srivastava N, Misra S, Mittal B. Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy. PLoS One. 2012;7:e40162.CrossRef
19.
Zurück zum Zitat Xu HL, Cheng JR, Andreotti G, Gao YT, Rashid A, Wang BS, et al. Cholesterol metabolism gene polymorphisms and the risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Carcinogenesis. 2011;32:58–62.CrossRef Xu HL, Cheng JR, Andreotti G, Gao YT, Rashid A, Wang BS, et al. Cholesterol metabolism gene polymorphisms and the risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Carcinogenesis. 2011;32:58–62.CrossRef
20.
Zurück zum Zitat Tsuchiya Y, Nakamura K, Yamamoto M, Kiyohara C. genetic susceptibility to gallbladder cancer in Japanese. Nihon Rinsho Jpn J Clin Med. 2006;64 Suppl 1:336–8. Tsuchiya Y, Nakamura K, Yamamoto M, Kiyohara C. genetic susceptibility to gallbladder cancer in Japanese. Nihon Rinsho Jpn J Clin Med. 2006;64 Suppl 1:336–8.
21.
Zurück zum Zitat Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP. Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg. 2011;66:10–7.CrossRef Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP. Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg. 2011;66:10–7.CrossRef
22.
Zurück zum Zitat Dova L, Pentheroudakis G, Georgiou I, Malamou-Mitsi V, Vartholomatos G, Fountzilas G, et al. Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastasis. 2007;24:79–86.CrossRef Dova L, Pentheroudakis G, Georgiou I, Malamou-Mitsi V, Vartholomatos G, Fountzilas G, et al. Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastasis. 2007;24:79–86.CrossRef
23.
Zurück zum Zitat Ortiz-Padilla C, Gallego-Ortega D, Browne BC, Hochgrafe F, Caldon CE, Lyons RJ, et al. Functional characterization of cancer-associated Gab1 mutations. Oncogene. 2013;32:2696–702.CrossRef Ortiz-Padilla C, Gallego-Ortega D, Browne BC, Hochgrafe F, Caldon CE, Lyons RJ, et al. Functional characterization of cancer-associated Gab1 mutations. Oncogene. 2013;32:2696–702.CrossRef
24.
Zurück zum Zitat Wang D, Paria BC, Zhang Q, Karpurapu M, Li Q, Gerthoffer WT, et al. A role for Gab1/shp2 in thrombin activation of pak1: gene transfer of kinase-dead pak1 inhibits injury-induced restenosis. Circ Res. 2009;104:1066–75.CrossRef Wang D, Paria BC, Zhang Q, Karpurapu M, Li Q, Gerthoffer WT, et al. A role for Gab1/shp2 in thrombin activation of pak1: gene transfer of kinase-dead pak1 inhibits injury-induced restenosis. Circ Res. 2009;104:1066–75.CrossRef
25.
Zurück zum Zitat Zhang Y, Li Z, Yang M, Wang D, Yu L, Guo C, et al. Identification of grb2 and gab1 coexpression as an unfavorable prognostic factor for hepatocellular carcinoma by a combination of expression profile and network analysis. PLoS One. 2013;8:e85170.CrossRef Zhang Y, Li Z, Yang M, Wang D, Yu L, Guo C, et al. Identification of grb2 and gab1 coexpression as an unfavorable prognostic factor for hepatocellular carcinoma by a combination of expression profile and network analysis. PLoS One. 2013;8:e85170.CrossRef
26.
Zurück zum Zitat Naji F, Attaleb M, Laantri N, Benchakroun N, El Gueddari B, Benider A, et al. Identification of g2607a mutation in EGFR gene with a significative rate in Moroccan patients with nasopharyngeal carcinoma. Cell Mol Biol. 2010;56(Suppl):OL1442–6.PubMed Naji F, Attaleb M, Laantri N, Benchakroun N, El Gueddari B, Benider A, et al. Identification of g2607a mutation in EGFR gene with a significative rate in Moroccan patients with nasopharyngeal carcinoma. Cell Mol Biol. 2010;56(Suppl):OL1442–6.PubMed
27.
Zurück zum Zitat Giovannetti E, Erdem L, Olcay E, Leon LG, Peters GJ. Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. Front Biosci. 2011;16:116–30.CrossRef Giovannetti E, Erdem L, Olcay E, Leon LG, Peters GJ. Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. Front Biosci. 2011;16:116–30.CrossRef
28.
Zurück zum Zitat Weiss GA, Rossi MR, Khushalani NI, Lo K, Gibbs JF, Bharthuar A, et al. Evaluation of phosphatidylinositol-3-kinase catalytic subunit (pik3ca) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. J Gastrointest Oncol. 2013;4:20–9.PubMedPubMedCentral Weiss GA, Rossi MR, Khushalani NI, Lo K, Gibbs JF, Bharthuar A, et al. Evaluation of phosphatidylinositol-3-kinase catalytic subunit (pik3ca) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. J Gastrointest Oncol. 2013;4:20–9.PubMedPubMedCentral
29.
Zurück zum Zitat Mason RA, Morlock EV, Karagas MR, Kelsey KT, Marsit CJ, Schned AR, et al. Egfr pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis. 2009;30:1155–60.CrossRef Mason RA, Morlock EV, Karagas MR, Kelsey KT, Marsit CJ, Schned AR, et al. Egfr pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis. 2009;30:1155–60.CrossRef
30.
Zurück zum Zitat Ren Y, Chen Z, Chen L, Fang B, Win-Piazza H, Haura E, et al. Critical role of shp2 in tumor growth involving regulation of c-myc. Genes Cancer. 2010;1:994–1007.CrossRef Ren Y, Chen Z, Chen L, Fang B, Win-Piazza H, Haura E, et al. Critical role of shp2 in tumor growth involving regulation of c-myc. Genes Cancer. 2010;1:994–1007.CrossRef
31.
Zurück zum Zitat Frey UH, Eisenhardt A, Lummen G, Rubben H, Jockel KH, Schmid KW, et al. The t393c polymorphism of the g alpha s gene (gnas1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2005;14:871–7.CrossRef Frey UH, Eisenhardt A, Lummen G, Rubben H, Jockel KH, Schmid KW, et al. The t393c polymorphism of the g alpha s gene (gnas1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2005;14:871–7.CrossRef
32.
Zurück zum Zitat Frey UH, Alakus H, Wohlschlaeger J, Schmitz KJ, Winde G, van Calker HG, et al. Gnas1 t393c polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:5071–7.CrossRef Frey UH, Alakus H, Wohlschlaeger J, Schmitz KJ, Winde G, van Calker HG, et al. Gnas1 t393c polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:5071–7.CrossRef
33.
Zurück zum Zitat Lehnerdt GF, Franz P, Winterhoff S, Bankfalvi A, Grehl S, Lang S, et al. The gnas1 t393c polymorphism predicts survival in patients with advanced squamous cell carcinoma of the larynx. Laryngoscope. 2008;118:2172–6.CrossRef Lehnerdt GF, Franz P, Winterhoff S, Bankfalvi A, Grehl S, Lang S, et al. The gnas1 t393c polymorphism predicts survival in patients with advanced squamous cell carcinoma of the larynx. Laryngoscope. 2008;118:2172–6.CrossRef
34.
Zurück zum Zitat Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012;28:266–72.CrossRef Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012;28:266–72.CrossRef
35.
Zurück zum Zitat Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142:1021–31. e1015.CrossRef Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142:1021–31. e1015.CrossRef
36.
Zurück zum Zitat Castro FA, Koshiol J, Hsing AW, Gao YT, Rashid A, Chu LW, et al. Inflammatory gene variants and the risk of biliary tract cancers and stones: a population-based study in china. BMC Cancer. 2012;12:468.CrossRef Castro FA, Koshiol J, Hsing AW, Gao YT, Rashid A, Chu LW, et al. Inflammatory gene variants and the risk of biliary tract cancers and stones: a population-based study in china. BMC Cancer. 2012;12:468.CrossRef
37.
Zurück zum Zitat Goto Y, Ando T, Nishio K, Kawai S, Ishida Y, Naito M, et al. Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy. Int J Med Sci. 2007;4:1–6.CrossRef Goto Y, Ando T, Nishio K, Kawai S, Ishida Y, Naito M, et al. Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy. Int J Med Sci. 2007;4:1–6.CrossRef
38.
Zurück zum Zitat Mouradian M, Kikawa KD, Johnson ED, Beck KL, Pardini RS. Key roles for grb2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin e2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth. Prostaglandins Leukot Essent Fat Acids. 2014;90:105–15.CrossRef Mouradian M, Kikawa KD, Johnson ED, Beck KL, Pardini RS. Key roles for grb2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin e2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth. Prostaglandins Leukot Essent Fat Acids. 2014;90:105–15.CrossRef
39.
Zurück zum Zitat Hoeben A, Martin D, Clement PM, Cools J, Gutkind JS. Role of grb2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma. Int J Cancer J Int Cancer. 2013;132:1042–50.CrossRef Hoeben A, Martin D, Clement PM, Cools J, Gutkind JS. Role of grb2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma. Int J Cancer J Int Cancer. 2013;132:1042–50.CrossRef
40.
Zurück zum Zitat Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Doi S, et al. Genome-wide association study identifies three new susceptibility loci for adult asthma in the Japanese population. Nat Genet. 2011;43:893–6.CrossRef Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Doi S, et al. Genome-wide association study identifies three new susceptibility loci for adult asthma in the Japanese population. Nat Genet. 2011;43:893–6.CrossRef
41.
Zurück zum Zitat Gao L, Weck MN, Nieters A, Brenner H. Grb2-associated binder 1 (gab1) genetic polymorphism, Helicobacter pylori infection, and chronic atrophic gastritis among older adults from Germany. Mol Carcinog. 2010;49:869–73.CrossRef Gao L, Weck MN, Nieters A, Brenner H. Grb2-associated binder 1 (gab1) genetic polymorphism, Helicobacter pylori infection, and chronic atrophic gastritis among older adults from Germany. Mol Carcinog. 2010;49:869–73.CrossRef
Metadaten
Titel
Essential role of polymorphism of Gab1, EGFR, and EGF for the susceptibility of biliary tract cancer
verfasst von
Ling-qin Meng
Publikationsdatum
01.12.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2568-7

Weitere Artikel der Ausgabe 12/2014

Tumor Biology 12/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.